
# Vonoprazan (P-CAB) Pharmacokinetic Profile

## Basic Properties
| Property | Value | Notes |
|----------|--------|-------|
| Chemical Class | P-CAB | Potassium-Competitive Acid Blocker |
| Structure | Pyrrole derivative | With pyridine and fluorophenyl moieties |
| pKa | 9.06 | Higher than PPIs (4.0-5.0) |
| Molecular Weight | 461.5 g/mol | As fumarate salt |
| Protein Binding | 80% | Less than PPIs (95-98%) |

## Core Pharmacokinetic Parameters
| Parameter | Value | Comparison to PPIs |
|-----------|--------|-------------------|
| Tmax | 1.5-2.0 h | Similar (1.0-3.5 h) |
| Vd | 1050 L | Much larger (0.13-0.4 L/kg for PPIs) |
| CL/F | 97.5 L/h | Different clearance mechanism |
| t½ | 7.7 h | Longer (0.5-2.1 h for PPIs) |

## Route-Specific Parameters
| Parameter | Oral | Notes |
|-----------|-------|-------|
| Bioavailability | >67% | Based on urinary recovery |
| Food Effect | Minimal | No dosing restrictions |
| Absorption Site | Small intestine | pH-independent |
| Peak Concentration | 10-60 ng/mL | Dose-proportional |

## Special Population Effects
| Population | PK Changes | Clinical Impact |
|------------|------------|----------------|
| Hepatic Impairment | ↑ AUC 2.6× | Dose adjustment may be needed |
| Renal Impairment | ↑ AUC 2.4× | Dose adjustment may be needed |
| Elderly | ↓ CL 18-35% | Monitor in severe cases |
| CYP2C19 PM | ↓ CL 15-29% | Not clinically significant |

## Comparative pH Control (20mg dose)
| Parameter | Vonoprazan | PPIs |
|-----------|------------|------|
| Onset to pH >4 | 4 h | 4-5 h |
| Day 1 pH >4 holding time | 63% | 45-50% |
| Day 7 pH >4 holding time | 83% | 60-65% |
| Night-time pH control | Superior | Limited |

## Drug Interactions
| Interacting Drug | Effect | Management |
|-----------------|---------|------------|
| Clarithromycin | ↑ AUC 1.8× | Monitor |
| CYP3A4 inhibitors | ↑ exposure | Monitor |
| Digoxin | ↑ absorption | Monitor levels |

## Tissue Distribution
| Tissue/Site | Concentration Ratio* |
|-------------|---------------------|
| Gastric Tissue | >100,000:1 |
| Plasma | 1:1 |
| Other Tissues | Variable |
*Tissue:Plasma ratio

## Pharmacokinetic/Dynamic Terms and Definitions
| Term | Definition |
|------|------------|
| AUC | Area under the plasma concentration-time curve |
| CL/F | Apparent oral clearance |
| PM | Poor metabolizer |
| t½ | Elimination half-life |
| Tmax | Time to maximum concentration |
| Vd | Volume of distribution |
| ↑ | Increase |
| ↓ | Decrease |

## Clinical Advantages Over PPIs
1. Pharmacokinetic:
   - Longer half-life
   - pH-independent absorption
   - Less affected by CYP2C19 status
   - More consistent plasma levels

2. Pharmacodynamic:
   - Faster onset of action
   - More potent acid suppression
   - Better night-time pH control
   - More consistent response

## Special Clinical Considerations
- Dosing:
  - No timing restrictions relative to meals
  - Once daily dosing sufficient for most indications
  - Twice daily for H. pylori eradication
- Monitoring:
  - Liver function in severe hepatic impairment
  - Renal function in severe renal impairment
  - Drug interactions with CYP3A4 substrates
- Advantages:
  - More predictable response across populations
  - Better maintained acid suppression
  - Potential for improved H. pylori eradication